Cargando…

BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response

Colorectal cancer (CRC) is a heterogeneous disease, which in part explains the differential response to chemotherapy observed in the clinic. BH3 mimetics, which target anti-apoptotic BCL-2 family members, have shown potential in the treatment of hematological malignancies and offer promise for the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Le, Ramesh, Prashanthi, Steinmetz, Maxime, Medema, Jan Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067732/ https://www.ncbi.nlm.nih.gov/pubmed/33917026 http://dx.doi.org/10.3390/ijms22083811

Ejemplares similares

BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
por: Ramesh, Prashanthi, et al.
Publicado: (2020)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Sensitivity of canine hematological cancers to BH3 mimetics
por: Jegatheeson, Selvi, et al.
Publicado: (2022)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

Defining the susceptibility of colorectal cancers to BH3-mimetic compounds
por: Luo, Ming-Jie, et al.
Publicado: (2020)

Mitochondrial apoptosis and BH3 mimetics
por: Dai, Haiming, et al.
Publicado: (2016)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
por: Jullien, Maxime, et al.
Publicado: (2020)

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
por: Potter, Danielle S., et al.
Publicado: (2021)

On BH3 Mimetics and Ca(2+) Signaling
por: Ferdek, Pawel E., et al.
Publicado: (2017)

BH3 Mimetics for the Treatment of Prostate Cancer
por: Wolf, Philipp
Publicado: (2017)

The application of BH3 mimetics in myeloid leukemias
por: Parry, Narissa, et al.
Publicado: (2021)

Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
por: Koessinger, Anna L., et al.
Publicado: (2022)

BH3-mimetics: recent developments in cancer therapy
por: Townsend, Paul A., et al.
Publicado: (2021)

Hypericin, a potential new BH3 mimetic
por: Doroshenko, Anastasia, et al.
Publicado: (2022)

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
por: Stamelos, Vasileios A., et al.
Publicado: (2016)

The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2015)

Overcoming EMT-driven therapeutic resistance by BH3 mimetics
por: Keitel, Ulrike, et al.
Publicado: (2014)

Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
por: Montero, Joan, et al.
Publicado: (2022)

Computational modeling of DLBCL predicts response to BH3-mimetics
por: Cloete, Ielyaas, et al.
Publicado: (2023)

Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines
por: Koss, Brian, et al.
Publicado: (2016)

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
por: Mukherjee, Nabanita, et al.
Publicado: (2018)

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
por: Butterworth, Michael, et al.
Publicado: (2016)

Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine
por: Stamelos, Vasileios A, et al.
Publicado: (2012)

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
por: Soderquist, Ryan S., et al.
Publicado: (2018)

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
por: Mallick, David J., et al.
Publicado: (2020)

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
por: Ewald, Larissa, et al.
Publicado: (2019)

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models
por: Olesinski, Elyse A., et al.
Publicado: (2021)

Temperature‐sensitive Ovarian Carcinoma Cell Line (OvBH‐1)
por: Bar, Julia K., et al.
Publicado: (2002)

BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells
por: Reinhart, Ramona, et al.
Publicado: (2018)

DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis
por: Milani, Mateus, et al.
Publicado: (2017)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells
por: Broecker-Preuss, Martina, et al.
Publicado: (2015)

Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics
por: Cragg, Mark S, et al.
Publicado: (2007)

The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2011)

Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
por: Oakes, SR, et al.
Publicado: (2012)

Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies
por: Al-Zebeeby, Aoula, et al.
Publicado: (2019)

Selective Elimination of Culture-Adapted Human Embryonic Stem Cells with BH3 Mimetics
por: Cho, Seung-Ju, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hmsk413uditv20f3cmut4cba5o